Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 10, 2015, Pages 1846-1853.e1

  Lens, Sabela ^a,b   Rincón, Diego ^b,c   García Retortillo, Montserrat ^a   Albillos, Agustín ^b,d   Calleja, Jose Luis ^e   Bañares, Rafael ^b,c   Abraldes, Juan González ^a   Bosch, Jaume ^a,b   Sanchez Tapias, Jose Maria ^a,b   Forns, Xavier ^a,b   García Pagán, Juan Carlos ^a,b  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

^e HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Cirrhosis; HCV; HVPG; Treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; PEGINTERFERON ALPHA2A; RIBAVIRIN; ALPHA INTERFERON; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ANTIVIRAL THERAPY; ARTICLE; ASCITES; BACTERIAL PERITONITIS; CHILD PUGH SCORE; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG RESPONSE; ESOPHAGUS VARICES; ESOPHAGUS VARICES BLEEDING; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; PORTAL HYPERTENSION; PROTHROMBIN TIME; RISK FACTOR; SPAIN; THROMBOCYTE COUNT; VENOUS PRESSURE; VIRUS LOAD; CARCINOMA, HEPATOCELLULAR; COMPLICATION; FEMALE; HEPATITIS C, CHRONIC; LIVER FAILURE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS C, CHRONIC; HUMANS; HYPERTENSION, PORTAL; INTERFERON-ALPHA; LIVER FAILURE; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; RISK ASSESSMENT; SPAIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84941734168     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2015.04.013     Document Type: Article

References (31)

1. Poynard T., McHutchison J., Davis G.L., et al. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000, 32:1131-1137.
2. Bruno S., Battezzati P.M., Bellati G., et al. Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C. J Hepatol 2001, 34:748-755.
3. Toccaceli F., Laghi V., Capurso L., et al. Long-term liver histology improvement in patients with chronic hepatitis C and sustained response to interferon. J Viral Hepat 2003, 10:126-133.
4. Ripoll C., Groszmann R., Garcia-Tsao G., et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 2007, 133:481-488.
5. Wadhawan M., Dubey S., Sharma B.C., et al. Hepatic venous pressure gradient in cirrhosis: correlation with the size of varices, bleeding, ascites, and child's status. Dig Dis Sci 2006, 51:2264-2269.
6. Ripoll C., Groszmann R.J., Garcia-Tsao G., et al. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol 2009, 50:923-928.
7. Blasco A., Forns X., Carrion J.A., et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology 2006, 43:492-499.
8. Burroughs A.K., Groszmann R., Bosch J., et al. Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point?. Gut 2002, 50:425-427.
9. Rincon D., Ripoll C., Lo Iacono O., et al. Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis. Am J Gastroenterol 2006, 101:2269-2274.
10. Afdhal N., Zeuzem S., Kwo P., et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014, 370:1889-1898.
11. Afdhal N., Reddy K.R., Nelson D.R., et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014, 370:1483-1493.
12. Poordad F., Hezode C., Trinh R., et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014, 370:1973-1982.
13. Berzigotti A., Ashkenazi E., Reverter E., et al. Non-invasive diagnostic and prognostic evaluation of liver cirrhosis and portal hypertension. Dis Markers 2011, 31:129-138.
14. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. J Hepatol 2014, 61:642-659. American Association for the Study of Liver Diseases, European Association for the Study of the Liver.
15. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010, 53:397-417. European Association for the Study of the Liver.
16. de Franchis R. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2010, 53:762-768.
17. Bruix J., Sherman M., Llovet J.M., et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001, 35:421-430.
18. Bruix J., Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
19. Ishida J.H., Peters M.G., Jin C., et al. Influence of cannabis use on severity of hepatitis C disease. Clin Gastroenterol Hepatol 2008, 6:69-75.
20. D'Amico G., Pasta L., Morabito A., et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther 2014, 39:1180-1193.
21. Lens S., Gambato M., Londono M.C., et al. Interferon-free regimens in the liver-transplant setting. Semin Liver Dis 2014, 34:58-71.
22. Flamm S., Everson G., Charlton M., et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective, multicenter study. Hepatology 2014, 60:320A.
23. Qamar A.A., Grace N.D., Groszmann R.J., et al. Platelet count is not a predictor of the presence or development of gastroesophageal varices in cirrhosis. Hepatology 2008, 47:153-159.
24. Louie K.S., Micallef J.M., Pimenta J.M., et al. Prevalence of thrombocytopenia among patients with chronic hepatitis C: a systematic review. J Viral Hepat 2011, 18:1-7.
25. Koh C., Heller T., Haynes-Williams V., et al. Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy. Aliment Pharmacol Ther 2013, 37:887-894.
26. Morgan R.L., Baack B., Smith B.D., et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013, 158:329-337.
27. Lee Y.A., Friedman S.L. Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C?. Antiviral Res 2014, 107C:23-30.
28. Issa R., Zhou X., Constandinou C.M., et al. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology 2004, 126:1795-1808.
29. Llop E., Berzigotti A., Reig M., et al. Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors. J Hepatol 2012, 56:103-108.
30. Casu S., Berzigotti A., Abraldes J.G., et al. A prospective observational study on tolerance and satisfaction to hepatic haemodynamic procedures. Liver Int 2015, 35:695-703.
31. Groszmann R.J., Garcia-Tsao G., Bosch J., et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005, 353:2254-2261.